Brief: Onxeo announces first outcomes of Livatag preclinical plan

Valerio Therapeutics SA

12/09/2016 06:31

Sept 12 (Reuters) - Onxeo SA  C4X.PA : 
    * Onxeo announces first outcomes of Livatag preclinical plan 
    * Livatag nanoformulation leads to increased exposure and preferential affinity for liver, 
supporting current relive phase III study rationale 
    * Demonstrates enhanced effect in combination with immunotherapy onxeo announces first 
outcomes of Livatag preclinical plan 
 
Source text for Eikon:  urn:newsml:reuters.com:*:nBwbNvly7a 
Further company coverage:  C4X.PA  
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))